US Patent 8,754,257: Ferric Citrate Composition Claims, Auryxia Patent Scope, and Generic Entry Risk

US Patent 8,754,257 covers pharmaceutical compositions containing a defined form of ferric citrate with an intrinsic dissolution rate of 1.88 to 4.0 mg/cm²/min. The claims also cover specified daily amounts, 500 mg unit doses, and capsule formulations. The patent is associated with Keryx Biopharmaceuticals' ferric citrate product Auryxia, marketed for hyperphosphatemia in chronic kidney disease and iron-deficiency anemia in adults with non-dialysis-dependent chronic kidney disease.[1-3]

The principal commercial issue is claim 1. It combines a physical-property limitation, ferric citrate, with a therapeutic composition requirement. A product that contains ferric citrate but falls outside the claimed intrinsic dissolution-rate range would have a materially stronger noninfringement position, subject to testing methodology and claim construction.

What does US Patent 8,754,257 protect?

The patent protects a composition containing:

A form of ferric citrate.
An intrinsic dissolution rate of 1.88 to 4.0 mg/cm²/min.
A pharmaceutically suitable carrier.
An amount effective to reduce serum phosphate levels.

The patent does not broadly cover every ferric citrate product. The dissolution-rate range is a central claim limitation.

Claim	Protected subject matter	Commercial significance
1	Ferric citrate with intrinsic dissolution rate of 1.88-4.0 mg/cm²/min in a pharmaceutical composition effective to reduce serum phosphate	Broadest composition claim
2	Claim 1 with 2-30 g/day ferric citrate	Broad dosing range
3	Claim 1 with 4-15 g/day	Intermediate dosing range
4	Claim 1 with 2-12 g/day	Practical phosphate-binding range
5	Claim 1 with 2, 4, or 6 g/day	Specific dose selections
6	Claim 1 with 1 g/day	Separate low-dose fallback
7	Claim 1 with 500 mg per unit dosage form	Unit-dose protection
8	500 mg ferric citrate composition in a capsule	Narrow dosage-form claim

Claim 8 is the narrowest claim because it requires both a 500 mg unit dose and a capsule dosage form. The claim does not cover every capsule containing ferric citrate. The ferric citrate must also satisfy the intrinsic dissolution-rate range in claim 1.

How should the intrinsic dissolution-rate limitation be interpreted?

Intrinsic dissolution rate, or IDR, measures the dissolution rate of a substance under standardized conditions from a constant surface area. In this patent, the claimed range is 1.88 to 4.0 mg/cm²/min.

The limitation creates several potential infringement and validity questions:

Whether the accused product uses the same ferric citrate form.
Whether the test measures ferric citrate itself or a finished dosage form.
Whether the measured rate is based on a constant exposed surface area.
Which pH, medium, temperature, agitation, and analytical method apply.
Whether the result is reported as a single value, average, or range.
Whether an accused product with a value near 1.88 or 4.0 mg/cm²/min falls within the claim.

The range is likely to be treated as a numerical limitation rather than a descriptive statement. A product measuring 2.5 mg/cm²/min would ordinarily fall within the literal range. A product measuring 1.7 or 4.2 mg/cm²/min would not literally satisfy the limitation, although an equivalence theory could be asserted depending on prosecution history and the technical meaning of the parameter.

The prosecution history is important because the applicant may have relied on the IDR range to distinguish prior ferric citrate compositions. If so, arguments made to obtain the patent could restrict the patentee's ability to recapture values outside the range under the doctrine of equivalents.

What do claims 2 through 8 add?

Claims 2 through 8 are dependent claims that narrow the composition claim by adding dose or dosage-form limitations.

Dose-range claims

Claims 2, 3, and 4 overlap:

Claim 2: 2-30 g/day
Claim 3: 4-15 g/day
Claim 4: 2-12 g/day

Claim 3 is narrower than claim 2. Claim 4 is also narrower than claim 2, but it overlaps claim 3 from 4 to 12 g/day. These overlapping ranges provide alternative positions if a broader range is challenged for obviousness or lack of written description.

Claim 5 identifies 2, 4, and 6 g/day. It is more specific than the preceding ranges and may be useful against a product label that directs administration at one of those doses.

Claim 6 covers 1 g/day, which is outside the 2-30 g/day range in claim 2. It therefore operates as an independent fallback from claim 1 rather than as a logical narrowing of claim 2.

Unit-dose and capsule claims

Claim 7 covers a 500 mg unit dosage form. It does not expressly require a capsule, tablet, or other specific presentation.

Claim 8 requires:

500 mg ferric citrate;
the claimed 1.88-4.0 mg/cm²/min IDR;
a pharmaceutically suitable carrier; and
a capsule dosage form.

The marketed Auryxia product is generally identified as a ferric citrate tablet containing 1 gram of ferric citrate, equivalent to 210 mg of elemental iron.[2] That presentation is not the capsule required by claim 8. Claim 8 therefore has limited direct relevance to a conventional 1-gram tablet unless a relevant product contains a separate 500 mg capsule presentation.

What drug is associated with US Patent 8,754,257?

The patent is associated with ferric citrate, marketed in the United States as Auryxia by Keryx Biopharmaceuticals and later within the Japan Tobacco and Torii Pharmaceutical commercial structure.[2,4]

Auryxia received FDA approval under NDA 205874 in 2014 for control of serum phosphorus levels in adults with chronic kidney disease on dialysis.[3] FDA later approved an indication for treatment of iron-deficiency anemia in adults with non-dialysis-dependent chronic kidney disease.[2]

The product label recommends administration with meals. For hyperphosphatemia, the starting dose is commonly two 1-gram tablets three times daily, corresponding to 6 grams of ferric citrate per day. That dose falls within claim 5 and claim 4. The commercial label therefore aligns more closely with the dose-dependent claims than with claim 8's capsule requirement.[2]

What is the patent expiration date?

The expected nominal expiration date for US Patent 8,754,257 is March 19, 2027, based on the patent-family filing chronology and the standard 20-year patent term applicable to the relevant nonprovisional filing.[1]

Event	Date or status
Earliest reported priority period	March 19, 2007
Relevant US application filing	March 19, 2012
Patent issued	June 17, 2014
Expected nominal expiration	March 19, 2027
Patent term adjustment or extension	Must be confirmed from the issued patent and Orange Book records

The earliest priority date does not ordinarily control the 20-year term. For a US utility patent, term generally runs from the earliest effective nonprovisional filing date in the chain, subject to terminal disclaimers, patent-term adjustment, and patent-term extension.[5]

The patent should be distinguished from other Auryxia patents. Auryxia's exclusivity position has included separate composition, formulation, and method-of-use patents. Expiration of one patent does not automatically eliminate every patent-based barrier to generic entry.

What is the Orange Book status of US Patent 8,754,257?

US Patent 8,754,257 has been listed in the FDA Orange Book for Auryxia-related protection.[6] Orange Book listing is commercially important because an ANDA applicant must address listed patents through one of four certifications:

Paragraph I: no patent information has been submitted;
Paragraph II: the patent has expired;
Paragraph III: the applicant will wait until patent expiration; or
Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV certification can trigger Hatch-Waxman litigation if the NDA holder files an infringement action within the statutory period. A timely suit can impose a 30-month stay on FDA approval, subject to statutory exceptions.[7]

The Orange Book listing does not itself establish that every Auryxia formulation infringes every claim of the patent. Listing is an FDA regulatory record. Infringement remains dependent on the approved product, the generic's formulation, the ANDA's proposed labeling, and the asserted patent claims.

What Paragraph IV challenges affect ferric citrate products?

Generic ferric citrate applicants would face a significant Paragraph IV issue because claim 1 is drafted around a product attribute that can be tested in an ANDA development program. A generic applicant could pursue several strategies:

Strategy	Potential position against the patent
Different ferric citrate material	The product does not have the claimed form or IDR
IDR outside the claimed range	The composition falls below 1.88 or above 4.0 mg/cm²/min
Different dose or presentation	Dependent claims 2-8 do not apply
Invalidity challenge	The claimed IDR range and composition were anticipated or obvious
Measurement challenge	The patent lacks a sufficiently definite testing standard
Label-based defense	The proposed label does not direct the claimed phosphate-lowering use

The most credible design-around path is likely control of the ferric citrate material and its dissolution profile. A formulation that changes tablet excipients but retains ferric citrate within the claimed IDR range may still infringe claim 1. Excipients alone may not avoid the patent if the claim requires only a pharmaceutically suitable carrier.

What patent litigation affects Auryxia and ferric citrate?

The relevant litigation risk is concentrated in ANDA litigation involving generic Auryxia applicants. Keryx disclosed patent disputes and ANDA-related litigation concerning proposed generic versions of Auryxia in its public filings.[4]

The principal litigation questions are:

Whether the generic ferric citrate has an IDR within the claimed range.
Whether the generic's composition contains the same or an equivalent ferric citrate form.
Whether the generic label includes phosphate-control use in dialysis patients.
Whether the patent claims are enabled across the full IDR and dosing ranges.
Whether the asserted claims are obvious over earlier ferric citrate phosphate binders.
Whether any settlement permits a launch before March 2027.

A settlement agreement could resolve litigation without invalidating the patent. The commercial result may be a licensed launch date, a contingent launch right, or a launch tied to court outcomes involving other patents. A patent-by-patent review is necessary because a settlement involving one Auryxia patent may leave other listed patents in place.

How strong is the patent estate for Auryxia?

US Patent 8,754,257 has meaningful strength against a generic that uses the same ferric citrate material and falls within the IDR range. Its strength is lower against a product with a reproducibly different dissolution profile.

Strength factor	Assessment
Claim breadth	Moderate; claim 1 covers a composition but requires a narrow IDR range
Product relevance	High for ferric citrate phosphate-binding products
Dose coverage	Broad, with overlapping ranges and specific fallback doses
Tablet coverage	Stronger under claim 1 and dose claims than under claim 8
Capsule coverage	Narrow and specifically limited to 500 mg capsules
Testing burden	Potentially high because IDR methodology can drive the result
Design-around potential	Material, if a competitor can develop ferric citrate outside the claimed range
Validity exposure	Possible obviousness and definiteness issues centered on the IDR range
Regulatory leverage	High if listed and timely asserted under Hatch-Waxman

The estate is stronger as a product-composition barrier than as a standalone capsule patent. Claim 1 does not require a particular brand, tablet shape, excipient, packaging configuration, or manufacturing process.

What formulation patents and method-of-use patents also matter?

Auryxia's broader patent landscape includes distinct categories:

Composition patents

These cover ferric citrate material or compositions characterized by physical or chemical properties. US Patent 8,754,257 is in this category.

Formulation patents

Formulation claims may cover tablet composition, excipient ratios, coating, stability, disintegration, dissolution, or elemental-iron delivery. Such patents can remain relevant even when a generic changes the ferric citrate source.

Method-of-use patents

Method claims may cover treating hyperphosphatemia, reducing serum phosphate in dialysis patients, or treating iron-deficiency anemia in non-dialysis-dependent CKD. These claims raise label, induced-infringement, and skinny-label issues.

Manufacturing patents

Manufacturing claims may cover preparation, particle-size control, drying, milling, crystallization, or production of a ferric citrate form with the claimed IDR. Process patents are harder to assess from the finished dosage form but can create supply-chain barriers when the commercial material depends on a protected process.

Is biosimilar risk relevant to ferric citrate?

No. Ferric citrate is a small-molecule active pharmaceutical ingredient, not a biologic. The relevant competitors are ANDA applicants for generic ferric citrate, not biosimilar applicants under the Public Health Service Act.

The applicable regulatory route is generally an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Patent certification and potential Paragraph IV litigation are therefore more important than biosimilar interchangeability or the Biologics Price Competition and Innovation Act.[7,8]

What generic launch scenarios exist?

Three launch scenarios are commercially plausible:

Launch after patent expiry. A generic applicant certifies Paragraph III for the patent and waits until the relevant expiration date, subject to other listed patents and regulatory exclusivities.
At-risk launch after litigation or a favorable judgment. The applicant launches before patent expiration after obtaining a judgment of noninfringement, invalidity, or unenforceability, accepting potential damages exposure if the decision is later reversed.
Settlement-authorized launch. The NDA holder and generic applicant agree to a future entry date or other terms. The practical launch date depends on the full listed-patent estate, not only US Patent 8,754,257.

The core generic-entry risk is therefore not simply the March 2027 expiration date. It is whether a proposed generic can avoid the IDR limitation and whether other Auryxia patents extend effective protection beyond this patent.

What is the geographic coverage?

US Patent 8,754,257 provides rights only in the United States. It does not block sales in Canada, Europe, Japan, or other jurisdictions.

International coverage depends on corresponding national applications and granted patents in the relevant patent family. Claim scope, term, prosecution history, regulatory linkage, and litigation procedures differ by jurisdiction. A US claim directed to a specific IDR range may not have an equivalent claim abroad, even where the same priority application supports the family.

Key Takeaways

US Patent 8,754,257 principally protects ferric citrate compositions with an IDR of 1.88-4.0 mg/cm²/min.
Claim 1 is the principal barrier and does not depend on a specific tablet design.
Claims 2-6 cover commercial and fallback dosing positions, including 6 g/day and 1 g/day.
Claim 7 covers a 500 mg unit dose; claim 8 is limited to a 500 mg capsule.
Auryxia's standard 1-gram tablet and 6-gram daily starting regimen are more relevant to claims 1, 4, and 5 than claim 8.
The expected nominal expiration date is March 19, 2027, subject to patent-term adjustments, extensions, and terminal-disclaimer analysis.
Generic applicants' strongest technical defense is likely a ferric citrate material with an IDR outside the claimed range.
The patent is relevant to ANDA Paragraph IV strategy, not biosimilar litigation.
A complete launch analysis must account for Auryxia's separate formulation, method-of-use, and manufacturing patents.

FAQs

Can a generic ferric citrate tablet avoid US Patent 8,754,257 by using different excipients?

Not necessarily. Claim 1 requires a pharmaceutically suitable carrier but does not specify particular excipients. A different excipient system may still infringe if the ferric citrate has an IDR within the claimed range.

Does a 1-gram Auryxia tablet fall within the 500 mg capsule claim?

Claim 8 requires a 500 mg capsule. A 1-gram tablet does not literally satisfy that dosage-form limitation. The broader claims may remain relevant.

Does a ferric citrate product with an IDR of exactly 4.0 mg/cm²/min fall within the patent?

Yes, the stated claim range includes both endpoints. A product with an IDR of exactly 4.0 mg/cm²/min would ordinarily satisfy the numerical limitation, assuming the prescribed testing method is used.

Can FDA approval proceed while a Paragraph IV lawsuit is pending?

FDA approval may be delayed by the Hatch-Waxman 30-month stay when the statutory requirements are met. The stay does not itself determine infringement or validity.[7]

Are iron-deficiency-anemia uses covered by the same patent claims?

The supplied claims are directed to compositions effective to reduce serum phosphate levels. They do not expressly recite treatment of iron-deficiency anemia. Separate method-of-use patents and FDA-approved labeling must be analyzed for that indication.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,754,257, Ferric citrate compositions and methods of use.
U.S. Food and Drug Administration. (2024). Auryxia (ferric citrate) tablets: Prescribing information.
U.S. Food and Drug Administration. (2014). Auryxia approval letter, NDA 205874.
Keryx Biopharmaceuticals, Inc. (2014-2018). Annual reports and securities filings concerning Auryxia intellectual property and ANDA litigation.
United States Code, 35 U.S.C. §§ 154, 156.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book.
United States Code, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulatory guidance.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004213819	⤷ Start Trial
Australia	2006279333	⤷ Start Trial
Australia	2007210090	⤷ Start Trial
Australia	2007210096	⤷ Start Trial
Canada	2516471	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,754,257

Summary for Patent: 8,754,257